CoChat

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

Open access
Drost, Rinske, Dhillon, Kiranjit K., van der Gulden, Hanneke, van der Heijden, Ingrid, Brandsma, Inger, Cruz, Cristina, Chondronasiou, Dafni, Castroviejo-Bermejo, Marta, Boon, Ute, Schut, Eva, van der Burg, Eline, Wientjens, Ellen, Pieterse, Mark, Klijn, Christiaan, Klarenbeek, Sjoerd, Loayza-Puch, Fabricio, Elkon, Ran, van Deemter, Liesbeth, Rottenberg, Sven, van de Ven, Marieke, Dekkers, Dick H.W., Demmers, Jeroen A.A., van Gent, Dik C., Agami, Reuven, Balmaña, Judith, Serra, Violeta, Taniguchi, Toshiyasu, Bouwman, Peter, Jonkers, Jos · 2016 · Journal of Clinical Investigation
Cited by 139

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Heterozygous germline mutations in breast cancer 1 (BRCA1) strongly predispose women to breast cancer. BRCA1 plays an important role in DNA double-strand break (DSB) repair via homologous recombination (HR), which is important for tumor suppression. Although BRCA1-deficient cells are highly sensitive to treatment with DSB-inducing agents through their HR deficiency (HRD), BRCA1-associated tumors display heterogeneous responses to platinum drugs and poly(ADP-ribose) polymerase (PARP) inhibitors in clinical trials. It is unclear whether all pathogenic BRCA1 mutations have similar effects on the response to therapy. Here, we have investigated mammary tumorigenesis and therapy sensitivity in mice carrying the Brca1185stop and Brca15382stop alleles, which respectively mimic the 2 most common BRCA1 founder mutations, BRCA1185delAG and BRCA15382insC. Both the Brca1185stop and Brca15382stop mutations predisposed animals to mammary tumors, but Brca1185stop tumors responded markedly worse to HRD-targeted therapy than did Brca15382stop tumors. Mice expressing Brca1185stop mutations also developed therapy resistance more rapidly than did mice expressing Brca15382stop. We determined that both murine Brca1185stop tumors and human BRCA1185delAG breast cancer cells expressed a really interesting new gene domain-less (RING-less) BRCA1 protein that mediated resistance to HRD-targeted therapies. Together, these results suggest that expression of RING-less BRCA1 may serve as a marker to predict poor response to DSB-inducing therapy in human cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci70196

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

Metadata

Authors
Drost, R., Dhillon, K. K., van der Gulden, H., van der Heijden, I., Brandsma, I., Cruz, C., Chondronasiou, D., Castroviejo-Bermejo, M., Boon, U., Schut, E., van der Burg, E., Wientjens, E., Pieterse, M., Klijn, C., Klarenbeek, S., Loayza-Puch, F., Elkon, R., van Deemter, L., Rottenberg, S., van de Ven, M., Dekkers, D. H. W., Demmers, J. A. A., van Gent, D. C., Agami, R., Balmaña, J., Serra, V., Taniguchi, T., Bouwman, P., & Jonkers, J.
Venue
Journal of Clinical Investigation
Published
2016-07-25
Volume
126
Issue
8
Pages
2903-2918
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2504554482
Cited by
139
References
14
FWCI
10.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.